Phase 3 AGENT Study: Primary Endpoint Is Response Rate, Tumor Shrinkage, & PFS

Anders Rabbe CEO Of Isofol Medical Discusses Phase 3 AGENT Study: Primary Endpoint Is Response Rate, Tumor Shrinkage, & PFS .